MoonLake Immunotherapeutics

MLTX Nasdaq SEC CIK 1821586
Follow MoonLake Immunotherapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$79.5M −14.1% vs same quarter last year
EPS, diluted −$0.93 +15.5% vs same quarter last year
Operating cash flow −$63.4M −42.3% vs same quarter last year
Operating income −$79.9M −11.8% vs same quarter last year
Net income by quarter
−$45.6M
−$39.9M
−$55.2M
−$69.7M
−$62.4M
−$69.7M
−$61.8M
−$79.5M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income6 fiscal years
−$300M−$200M−$100M$0FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$227.3M
FY24−$118.9M
FY23−$36M
FY22−$50M
FY21−$4.5M
FY20-
Free cash flowOperating cash flow minus capital expenditure
−$200M−$150M−$100M−$50M$0FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$196M
FY24−$117.1M
FY23−$43.1M
FY22−$55.9M
FY21-
FY20-
Returned to shareholdersDividends paid and shares bought back
$0$20$40$60FY20FY21FY22FY23FY24FY25
Show the numbers
YearBuybacks
FY25-
FY24$50
FY23$0
FY22$0
FY21-
FY20-